EPI-7386

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for EPI-7386, covering 2025-02-03 to 2025-05-29. Get the full timeline:

Most recent: Clinical Trial Update: Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer [Phase 2]

See pricing